Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1627 | Thyroid (non-cancer) | ICEECE2012

Serum chemokine CXCL10 is increased in chronic autoimmune thyroiditis associated with autoimmune gastritis

Santaguida M. , Ferrari S. , Duca S Del , Fallahi P. , Centanni M. , Antonelli A.

Autoimmune thyroiditis (AT) may occur as a single disease or associated with further endocrine and non endocrine autoimmune diseases (NEAD). Chronic autoimmune gastritis (CAG) is the more frequently associated NEAD. A prevalent Th1-representative pattern of cytokines and chemokines has been described in isolated autoimmune thyroiditis. However, the behaviour of chemokines when AT is associated with CAG is not known. Aim of the study has been to measure serum levels of CXCL10 i...

ea0029p1630 | Thyroid (non-cancer) | ICEECE2012

Beta (CCL2) and alpha (CXCL10) chemokines modulation by cytokines and by peroxisome proliferator-activated receptor-alpha agonists in Graves’ ophthalmopathy

Antonelli A. , Ferrari S. , Sellari-Franeschini S. , Corrado A. , Mancusi C. , Ferrini M. , Ferrannini E. , Fallahi P.

Introduction: No study has evaluated the effect of cytokines on the prototype beta chemokine (C-C motif) ligand (CCL)2 in Graves’ ophthalmopathy (GO), nor of peroxisome proliferator-activated receptor (PPAR)alpha activation on this chemokine secretion in fibroblasts or preadipocytes in GO.Design and methods: We have tested the interferon (IFN)gamma and tumor necrosis factor (TNF)alpha effect on CCL2, and for comparison on the prototype alpha chemoki...

ea0029p1780 | Thyroid cancer | ICEECE2012

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo

Antonelli A. , Bocci G. , La Motta C. , Ferrari S. , Fallahi P. , Ruffilli I. , Di Domenicantonio A. , Da Settimo F. , Miccoli P.

Introduction: The antitumor activity of a novel cyclic amide, CLM94, with anti-VEGFR-2 and antiangiogenic activity, in primary anaplastic thyroid cancer (ATC) cells in vitro and in vivo, has been studied.Design and Methods: CLM94 was tested: i) in two human cell lines (HMVEC-d, dermal microvascular endothelial cells; 8305C, undifferentiated thyroid cancer) at 0.001–100 mcM; ii) in ATC cells at the concentrations of 10, 30, 50 mcM; iii)...